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RASSF1A is one of the most frequently inactivated tumor suppressors yet identiﬁed in
human cancer. It is pro-apoptotic and appears to function as a scaffolding protein that
interacts with a variety of other tumor suppressors to modulate their function. It can also
complex with the Ras oncoprotein and may serve to integrate pro-growth and pro-death
signaling pathways.A SNPhas been identiﬁed that is present in approximately 29%of Euro-
pean populations [rs2073498, A(133)S]. Several studies have now presented evidence that
this SNP is associated with an enhanced risk of developing breast cancer.We have used a
proteomics based approach to identify multiple differences in the pattern of protein/protein
interactions mediated by the wild type compared to the SNP variant protein.We have also
identiﬁed a signiﬁcant difference in biological activity between wild type and SNP variant
protein. However, we have found only a very modest association of the SNP with breast
cancer predisposition.
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INTRODUCTION
RASSF1A is a tumor suppressor that suffers epigenetic inactivation
in over 50% of human tumors (Dammann et al., 2005; Donninger
et al., 2007; van der and Adams, 2007). Knockout RASSF1A mice
demonstrate an enhanced predisposition to develop spontaneous
tumors (Dammann et al., 2000) and this effect is ampliﬁed in a
p53 null mouse background (Tommasi et al., 2011). RASSF1A is
pro-apoptotic and can induce cell cycle arrest in G2 and in G1
(Shivakumar et al., 2002; Vos et al., 2004, 2006). RASSF1A has no
enzymatic activity, but appears to act by modulating microtubule
polymerization and by scaffolding other tumor suppressors. Sev-
eral tumor suppressor pathways are now known to be directly
modulated by RASSF1A including MOAP-1/Bax (Baksh et al.,
2005; Vos et al., 2006), the hippo pathway (Guo et al., 2007), and
p53 (Song et al., 2008).
KEY RASSF1A INTERACTIONS
RASSF1A and K-Ras
RASSF1A contains a Ras association domain and a cysteine rich
domain (CRD). By analogy to the classic Ras effector Raf, both
of these domains have the potential to bind directly to Ras onco-
proteins (Drugan et al., 1996). RASSF1A can be detected in an
endogenous complex with Ras (Calvisi et al., 2006), can form a
complex with exogenously expressed activated K-Ras and serve as
pro-apoptotic K-Ras effector (Vos et al., 2006; Donninger et al.,
2007). There remains some controversy over the physiological
nature of the interaction between Ras and RASSF1A. This may
have arisen because only the K-Ras speciﬁc isoform interacts with
RASSF1A, and the K-Ras protein must be post-translationally
modiﬁed to support the interaction (Donninger et al., 2007).
Moreover, our experience working with the Ras effector Raf-1
showed us that inclusion of EDTA or strong detergents in the
binding buffer can destroy the interaction between Ras and CRD
structures (data not shown).
RASSF1A and microtubules
Early work showed that RASSF1A forms a complex with the
microtubule network in cells and co-immunoprecipitates with
most tubulin isoforms. Moreover, the interaction with RASSF1A
appears to promote a robust,Taxol-like increase in the polymeriza-
tion of microtubules (Liu et al., 2003; Dallol et al., 2004; Vos et al.,
2004). Yeast two-hybrid studies have found that RASSF1A can
directly bind a series of microtubule associating proteins (MAPS)
including MAP1a/MAP1b, C19ORF5 (Dallol et al., 2004), and
MAP4 (Vos et al., 2004). Thus, it seems likely that the association
with microtubules is indirect. Interestingly, certain tumor derived
mutants of RASSF1A appear to lose the ability to associate with
speciﬁc tubulin isoforms (El-Kalla et al., 2010). Moreover, deletion
mutants of RASSF1A that lose the ability to complex with micro-
tubules are defective for the induction of cell cycle arrest (Vos
et al., 2004). These data suggest that the interaction of RASSF1A
with microtubules may be unusually complex and essential for its
tumor suppressing activity.
RASSF1A and MOAP-1/Bax
MOAP-1 is a BH3 (Bcl-2 homology3) domain containing pro-
tein that binds and activates the pro-apoptotic effector Bax (Tan
et al., 2005). RASSF1A was found to bind directly to MOAP-1
and thereby stimulate Bax apoptotic activity (Baksh et al., 2005;
Vos et al., 2006). As MOAP-1 can associate with TNF-R1 and
TRAIL-R1/DR4 death receptors, this links RASSF1A into TNF
alpha/TRAIL death signaling pathways (Baksh et al., 2005). The
interaction of RASSF1A and MOAP-1 is enhanced by the presence
of activated K-Ras. Thus RASSF1A can act as a connector between
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Ras and Bax. Cells knocked out for RASSF1A exhibit reduced Bax
activation and apoptosis when transfected with activated K-Ras
(Baksh et al., 2005; Vos et al., 2006).
RASSF1A and the Hippo pathway
RASSF1Adirectly binds and activates the pro-apoptoticMST1 and
MST2 kinases (Praskova et al., 2004; Avruch et al., 2006). These
kinases drive the hippo pathway by phosphorylating and kinases
LATs1 and LATs2 (Harvey and Tapon, 2007). These kinases then
phosphorylate the transcription factors YAP and TAZ, which in
turn activate the p73 tumor suppressor (Matallanas et al., 2007).
The full role of RASSF1A in this pathway may be more complex as
it also directly binds a protein called Salvador. Salvador may serve
as an adaptor to promote the phosphorylation of LATs by MST
(Guo et al., 2007). However, Salvador also appears to be a tumor
suppressor in its own right,with signiﬁcant functions independent
of the classic hippo pathway (Donninger et al., 2011).
In summary, we now know that RASSF1A can complex with
multiple known tumor suppressors and modulate their activity.
This gives RASSF1A the potential to serve as a tumor suppressor
node, integrating the activity of multiple tumor suppressors and
connecting K-Ras to their action.
THE rs2073498A SNP
Several SNPs have been identiﬁed in the RASSF1A gene. The best
characterized (rs2073498) is a C–A variation resulting in the pres-
ence of a Serine instead of an Alanine at amino acid 133 in the
RASSF1A protein. This A(133)S variant protein has been asso-
ciated with a reduced ability to regulate the cell cycle at G1/S
(Shivakumar et al., 2002). Structurally, the A133S variant falls in
a rather an intriguing position in the RASSF1A protein, within
the minimal microtubule association domain (residues 120–185;
Vos et al., 2004). Although the A(133)S variant retains an overtly
similar association with microtubules as the wild type protein, it
is defective for the interaction with gamma and alpha (but not
beta) tubulin (El-Kalla et al., 2010). Moreover, the change of Ala-
nine133 to a Serine destroys a consensus phosphorylation site
for the ATM kinase, an essential component of the DNA dam-
age response (Hamilton et al., 2009). In fact it generates a new
consensus phosphorylation site for several other kinases, includ-
ing Casein kinase II. Thus, the biology and the regulation of the
A(133)S variant may be signiﬁcantly different to that of the wild
type protein.
THE rs2073498 SNP AND CANCER PREDISPOSITION
In 2005, an analysis was performed to determine if SNPs detected
in RASSF1A might have any association with the development
of cancer (Schagdarsurengin et al., 2005). A striking result was
obtained showing that the rs2073498 SNP was present in approxi-
mately 2%of non-cancer patient controls but almost 20%of breast
cancer patients. A subsequent study (Gao et al., 2008) showed a
much more modest increased association of the SNP with breast
cancer development but linked it to a predisposition to early onset
of disease in BRCA1 mutant positive patients. The presence of the
SNP in the normal control population was found to be dramati-
cally higher in this study (∼18%). Moreover, the dbSNP (Sherry
et al., 2001) gives a frequencyof∼29% for the SNP innormal Euro-
pean populations. A third study (Bergqvist et al., 2010) has now
been performed and has been unable to conﬁrm a link between the
SNP and breast cancer predisposition. However, this study did not
address age of onset issues. This study also found a much higher
frequency of the SNP in their non-cancer controls. Thus, there
remains a controversy regarding the importance of the SNP for
the development of breast cancer.
Here we have sought to address the role of the rs2073498 SNP
in RASSF1A function and in breast cancer predisposition. We
have compared the biological characteristics of the wild type and
SNP derived proteins and identiﬁed differences in protein/protein
interactions as well as in the effects of the proteins on cellular
adhesion. We have also screened a larger cohort of breast cancer
patients for the presence of the SNP. However, we found only a
very modest increase in breast cancer amongst carriers of the SNP.
RESULTS
FREQUENCY OF THE rs2073498 SNP IN BREAST CANCER
We have analyzed the largest breast cancer population group to
date for the presence of the rs2073498 C/A SNP in RASSF1A. This
group consisted of a primarily Caucasian, Non-African American
(NAA) group of 1118 normal, and 1230 breast cancer patients as
well as an African American (AA) group of 658 normal and 742
breast cancer patients (Table 1). We ﬁnd that 20% of the normal
NAA population are Heterozygous, and 2% are Homozygous, for
the allele. Curiously, only∼6.1%of 658 normalAAwomen carried
the allele. This shows that there is a dramatic racial disparity in the
presence of the allele. We observed a very modest 4.5% (odds ratio
1.066) increase in frequency for the presence of the SNP in NAA
populations with breast cancer. This is not considered statistically
signiﬁcant (P-value 0.6). No increase was observed in the much
smaller AA sample. In fact, the SNP was less present in the AA
breast cancer patients.
Table 1 | Frequency of the A(133)S SNP in normal and breast cancer
patient populations of Non-African American and African American
women.
RASSF1A Codonl33Ala/Ser
Ser (S)=A
Ala (A)=C
rs 2073498
African Americans Cases (N =742) Controls (N =658)
Allele frequencies C =0.98 C =0.97
Chi-square P -value=0.03 A=0.02 A=0.03
Genotype frequencies C/C 713 (96%) C/C 616 (94%)
Chi-square P -value=0.08 C/A 29 (4%) C/A 41 (6%)
A/AO A/A 1(0.1%)
HardyWeinberg test P -value 0.59 0.71
Non-African Americans Cases (N =1230) Controls (N =1118)
Allele frequencies C =0.88 C =0.88
Chi-square P -value= A=0.12 A=0.12
Genotype frequencies C/C 952 (77%) C/C 875 (78%)
Chi-square P -value= C/A 258 (21%) C/A 223 (20%)
A/A 20 (2%) A/A 20 (2%)
HardyWeinberg test P -value 0.60 0.19
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When breaking up the NAA breast cancers by sub-type, the
SNP was present in 22% of normal control samples and 26.3%
of Luminal A breast cancer patients (P-value= 0.094, odds ratio
1.4), no differences were detected in Luminal B or Triple negative
patients. Moreover, no signiﬁcant (P = 0.85) differences in age of
onset were observed (Table 2). However, data was not available to
consider the role of the BRCA1 mutation status in the samples.
We have also performed a series of experiments in an attempt
to determine if there are signiﬁcant differences in the biologi-
cal activity of between the wild type RASSF1A protein and the
A(133)S variant produced by the SNP allele that might support a
role in cancer predisposition.
THE RASSF1A A(133)S VARIANT ALTERS CELLULAR ADHESION
In order to examine any potential differences in biological activ-
ity between the wild type RASSF1A and the A(133)S variant,
we transfected H1299 lung carcinoma cells (RASSF1A negative)
with expression constructs to generate stable cell lines express-
ing approximately equal amounts of each protein (Figure 1). We
found little obvious difference in the rate of cell growth between
the matched pair of cells. However, we detected a signiﬁcant
increase in the degree of adhesion in theA(133)S variant compared
to the wild type RASSF1A expressing cells (Figure1). Whereas
transformed cells often exhibit reduced adhesion which correlates
with enhanced motility, here we found that the variant RASSF1A
expressing cells demonstrate stronger adhesion to the substratum
than the wild type RASSF1A expressing cells. However, there are
multiple examples where enhanced adhesion has been associated
with enhanced transformation (Kenny et al., 2008) or survival
(Tsujii and DuBois, 1995).
Table 2 | Average age of onset of breast cancer in wt vs. rs2073498
SNP patients.
Codon 133 status Number of patients Mean age of onset
C/C 952 51.323
C/A+A/A 278 51.003
T-tests give a P-value of 0.85.
FIGURE 1 |The A(133)S SNP induces enhanced adhesion. (A) H1299 cells
stably transfected with HA tagged RASSF1A expression vector were
assayed for the strength of their adhesion to culture dishes. The difference
between the wild type and the A(133)S variant transfected cells was
statistically signiﬁcant (P =0.03). (B) Levels of RASSF1A expression in the
stable cell lines was conﬁrmed by western analysis using an HA antibody.
THE RASSF1A A(133)S VARIANT EXHIBITS DIFFERENTIAL BINDING TO A
VARIETY OF POTENTIAL RASSF1A TARGETS
In an attempt to identify proteins which bind differentially
between the wild type and the SNP derived protein, we performed
a proteomic analysis of immunoprecipitations of wild type and
A(133)S RASSF1A transfected into 293-T cells. Problems in inter-
preting this type of experiment can arise because of the degree
of background. However, here we were focusing on differences
between the two forms of the protein rather than the total com-
position of the pull down. We identiﬁed a number of known
RASSF1A interacting proteins that bound to the same degree, such
as MST1 and C19ORF5 (Table 3, denoted in blue), but we also
identiﬁed a small group of proteins that appeared to exhibit dif-
ferential association (Table 3). Some proteins appeared to gain
association with the SNP derived variant, and some appeared to
lose association.
We have begun to validate these results by Western blot. Our
initial progress suggests that these results may be accurate as
MAP1a appeared to show differential binding when we performed
co-transfection/co-immunoprecipitation experiments (Figure 2).
This is a speciﬁc defect, as MAP4 showed equivalent binding.
Further validation is proceeding.
DISCUSSION
RASSF1A is an important tumor suppressor with the potential
to impact many different biological processes that are critical
to the development of cancer. The A(133)S SNP derived pro-
tein has now been shown to exhibit a number of subtle defects
in biological function. These include differential binding to vari-
ous interaction partners, differential effects on the cell cycle and
cellular adhesion. We have also recently observed a differential
interaction with components of the DNA repair machinery and
found that the A(133)S variant form of RASSF1A can act as
Table 3 | Summary of proteins identified as demonstrating differential
interactions with the wild type and A(133)S variant of RASSF1A.
Protein target RASSF1AWT RASSF1AA133S
Tau 0.26 0
AGR3/BCMP11 0 0.5
ANAPC7 0 0.15
Claudin 10 4 0
Vimentin 0.55 0
RASSF3 0.36 0
Map1a 0.68 0
Ksr 0.07 0.0
MST1 0.1 0.1
C190RF5 0.7 0.7
RASSF1A 4.3 3.8
Quantiﬁcation of interactions is shown as protein abundance factor (PAF). Essen-
tially this value is calculated from the total of uniqueMS/MS spectra that identiﬁed
each individual protein divided by the molecular weight (Dalton)×104. Proteins
denoted in blue are proteins that are already known to bind directly to RASSF1A.
Therefore, their presence in the screen at equivalent levels serves as an internal
control. The levels of RASSF1A expressed during the transfection can also be
seen to be similar (denoted in red).
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FIGURE 2 | Differential binding of the A(133)s RASSF1A variant to MAPs.
GFP–MAP1a (A) and GFP–MAP4 (B) were co-transfected into 293-T cells
with HA tagged RASSF1A constructs. Equally ﬂuorescent transfected
dishes were lysed, immunoprecipitated with GFP andWestern blotted with
HA and GFP.
a dominant negative in certain aspects of DNA repair (man-
uscript submitted). Thus it would be perfectly reasonable to
ﬁnd that the SNP is associated with an enhanced risk of cancer
development.
However, dramatic early results in breast cancer patients have
not yet been reproduced. We performed a larger study to deter-
mine if we could do so.We were unable to conﬁrm results showing
a strong association between presence of the SNP and breast can-
cer development. We found only a much more modest association
and only with the luminal A sub-type. Thus, the association of the
SNP with breast cancer appears to be more subtle than originally
anticipated and may be dependent upon a background of BRCA1
deﬁciency (Gao et al., 2008). Indeed, the most curious feature of
the initial breast cancer study is not the high frequency of the SNP
in the cancer patients, but rather the very low frequency reported
for the non-cancer patient controls. Unlike the other studies,most
of these controls were suffering from some non-cancer, malady of
the breast, mostly cystic diseases. Perhaps the low frequency of the
SNP in these patients is telling us that the SNP is protective against
cystic diseases.
The strongest correlation with cancer susceptibility described
so far for the rs2073498 SNP is with lung cancer in Japanese popu-
lations (Kanzaki et al., 2006). In Japan the SNP is present at∼11%
in the normal population and lung cancer patients were almost
twice as likely to carry the SNP (Kanzaki et al., 2006). This tissue
is likely to be exposed to mutagenic insults at a higher frequency
than breast cancer tissue. As we have recently observed reduced
DNA repair activity in lung tumor cells expressing the A(133)S
variant derived from the SNP (manuscript submitted), this tissue
may be more sensitive to the cancer predisposition effect. Thus, a
larger study in lung cancer could prove very interesting.
Our proteomics screen has identiﬁed several intriguing poten-
tial differences in the protein complexes formed by the wild type
and A(133)S variant. Most of the differences identiﬁed involved
proteins with known functions in cancer. These include proteins
that appear to lose association with the SNP derived variant and
those that appear to gain it. Claudin 10 is a tight junction pro-
tein with multiple functions (Gunzel et al., 2009) that has been
implicated in modulating invasion (Ip et al., 2007).Vimentin over-
expression in cancer has been documented and a potential role
in metastasis identiﬁed (Satelli and Li, 2011). Vimentin has been
implicated in adhesion (Ivaska et al., 2007) and so the differential
association might explain the differential adhesion promoted by
the two forms of RASSF1A (Figure 1).
The A(133)S variant of RASSF1A has previously been shown
to be defective for the interaction with gamma and alpha tubulin,
although the interaction with beta tubulin was retained (El-Kalla
et al., 2010). This implies that it is defective for the interac-
tion with MAPs which are already known to bind directly to
RASSF1A (Dallol et al., 2004). Potential differences in the inter-
action with the MAPs Tau and MAP1a were identiﬁed in the
screen. The defective interaction with MAP1a was conﬁrmed by
co-immunoprecipitation studies.
Ksr is thought to act as a scaffold facilitating the activation of
the Raf oncoprotein by Ras. Ksr can complex with a second Raf
scaffold calledCNK (Claperon andTherrien, 2007). CNKhas been
reported to be able to bind RASSF1A and to mediate some of the
apoptotic effects of RASSF1A (Rabizadeh et al., 2004).
RASSF3 remains themost obscuremember of theRASSF family
(Tommasi et al., 2002). In our hands it is pro-apoptotic butwe have
been unable to detect any loss of mRNA or protein expression in
human tumor cells (data not shown). It has, however, been impli-
cated in mediating resistance to transformation by deregulated
Her/Neu in breast cancer (Jacquemart et al., 2009).
ANAPC7 is a sub-unit of the anaphase promoting complex
(APC). The APC acts to regulate the levels of a variety of key com-
ponents of the cell cycle. RASSF1A has previously been implicated
in modulating APC activity via binding cdc20 (Song and Lim,
2004). However, this interaction remains controversial (Liu et al.,
2007).
AGR3/BCMP11 remains a relatively obscure protein but has
recently been associated with differentiation and survival in ovar-
ian cancer (King et al., 2011). It has also been identiﬁed as an
over-expressed protein in breast cancer (Adam et al., 2003). Fur-
ther validation, including endogenous co-immunoprecipitations,
will be required to validate the data set.
An important point that may be worth considering is that when
tumors lose expression of RASSF1A by promoter methylation,
a smaller isoform of RASSF1 called RASSF1C usually remains
(Richter et al., 2009). In these cells, the SNP will manifest at
a protein level as RASSF1C A(63)S. It is possible that it is this
protein, not RASSF1A A(133)S that may be driving any cancer
susceptibility phenotype. Indeed, some evidence has been pre-
sented that RASSF1C can serve as an oncogene (Reeves et al.,
2010).
A further consideration is that the SNP shows a dramatic dif-
ference in its occurrence between different racial populations.
According to the dbSNP (Sherry et al., 2001), the frequency of
the SNP is almost 15 times higher in European populations than
in African populations. Our studies based on populations in the
USA found an approximately fourfold higher frequency in NAAs
than inAAs. Therefore, to determine if the SNPpredisposes toward
cancer, perhaps we should focus on cancers that are more frequent
in the NAA populations such as ovarian (Ness et al., 2000). This
observation alsomeans that if study populations are not controlled
for race, then any epidemiology results obtained may be seriously
ﬂawed.
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MATERIALS AND METHODS
PLASMIDS AND DNA
RASSF1A plasmids have been described previously (Dallol et al.,
2004; Vos et al., 2006). GFP–MAP1a was a kind gift of Chien et al.,
2005; Chung Shan Medical University, Taichung, Taiwan).
TISSUE CULTURE AND WESTERN ANALYSIS
293-T cells were cultured and transfected as described previously
Vos and Clark (2005). After 24 h, transfected cells were lysed as
described previously Vos and Clark (2005) and immunoprecip-
itated with GFP-trap beads (Allele Biotech, Belgium) according
to the manufacturer’s instructions. The immunoprecipitates were
Western blotted with anti-GFP (Santa Cruz Bio, Santa Cruz, CA,
USA) and anti-HA antibodies (Sigma, St. Louis, MO, USA).
ADHESION ASSAYS
H1299 cells (ATCC, Manassas, VA, USA) were stably transfected
with RASSF1A wild type or mutant cloned in the vector pZIP-
neoHA (Fiordalisi et al., 2001). Cells were selected in G418 and
adhesion assays were performed as described in (Humphries,
2001). Essentially, cells were plated at 5 × 104 cells per well in
BSA-coated 96-well plates and allowed to adhere for 45 min at
37˚C. The medium was removed and the adhering cells ﬁxed and
stained with crystal violet. The dye was solubilized in 10% acetic
acid and absorbance at 570 nm was used as a measure of adhesion.
PROTEOMICS
Ten 10 cm dishes of 293-T cells were transfected with 5μg of
HA tagged RASSF1A expression plasmid. Cells were lysed and
immunoprecipitated with HA conjugated beads after 24 h. Sam-
ples were washed and subjected to trypsin digestion. Trypsin-
digested samples were analyzed by 2D-LC-MS/MS. Brieﬂy, protein
samples were digested with modiﬁed trypsin (Promega, Madison,
WI, USA) overnight at 37˚C as previously described (Cummins
et al., 2010). Resulting peptides were loaded onto an analytical
2D capillary chromatography column packed with strong cation
exchange (SCX) and C18 reversed-phase (RP) resin (Phenomenex,
Torrance,CA,USA). This biphasic column was attached to an ana-
lytical RP chromatography column with an integrated, laser pulled
emitter tip. Peptides were eluted from SCX with seven step gra-
dients of 5, 10, 15, 30, 50, 70, and 100% of 500 mM ammonium
acetate. Following each SCX elution step, peptides were ionized
and eluted into a linear ion trap mass spectrometer according to
the following linear HPLC gradient: 20 min: 0% B, 80 min: 40% B,
90 min: 60% B at a ﬂow rate of 200 nl/min (mobile phase A: 5%
acetonitrile/0.1% formic acid and mobile phase B: 80% acetoni-
trile/0.1% formic acid). MS/MS spectra were acquired with a LTQ
ion trap mass spectrometer (Thermo Fisher Scientiﬁc, Waltham,
MA,USA). Protein identiﬁcationwas performedwith Sequest Sor-
cerer (Sage-N Research, San Jose, CA, USA), which was set up
to search a FASTA formatted human protein database (Human
RefSeq) with a fragment ion mass tolerance of 1.00 Da and a par-
ent ion tolerance of 1.2 Da. High-probability peptide and protein
assignments from were made using Peptide and Protein Prophet
algorithms (Nesvizhskii et al., 2003). Abundance of each identi-
ﬁed protein was determined by normalizing the number of unique
spectral counts matching to the protein by its predicted molecular
weight. This value has been termed a protein abundance factor
(Powell et al., 2004). Comparative analysis was performed with an
in-house, web-based program (McAfee et al., 2006).
GENOMICS
Experiments were performed as described previously (Nyante
et al., 2011). Essentially, the Carolina Breast Cancer Study (CBCS)
is an IRB approved, comprehensive, interdisciplinary investigation
into the causes of invasive and in-situ breast cancer amongAA and
whitewomen inNorthCarolina. Enrollmentwas conducted in two
phases, Phase 1 (1993–1996) and Phase 2 (1996–2001), and the
total number of enrolled participants is 4333. Phase 1 and Phase
2 of the study includes 2311 cases (894 AA, 1417 NAA, primar-
ily Caucasian) and 2022 controls (788 AA, 1234 NAA). Peripheral
blood lymphocytes were collected and DNA extracted for 90%
of participants. Genotyping was completed using the Illumina
Golden Gate platform: 96% of samples had call rates greater than
95; 90% of SNPs were successfully genotyped; control DNA sam-
ples had concordance rates of 99.9%. SAS was used to calculate
chi-squared tests and Hardy Weinberg tests.
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